Abstract
Abstract
Purpose
In this work, we address image segmentation in the scope of dosimetry using deep learning and make three main contributions: (a) to extend and optimize the architecture of an existing convolutional neural network (CNN) in order to obtain a fast, robust and accurate computed tomography (CT)-based organ segmentation method for kidneys and livers; (b) to train the CNN with an inhomogeneous set of CT scans and validate the CNN for daily dosimetry; and (c) to evaluate dosimetry results obtained using automated organ segmentation in comparison with manual segmentation done by two independent experts.
Methods
We adapted a performant deep learning approach using CT-images to delineate organ boundaries with sufficiently high accuracy and adequate processing time. The segmented organs were consequently used as binary masks for further convolution with a point spread function to retrieve the activity values from quantitatively reconstructed SPECT images for “volumetric”/3D dosimetry. The resulting activities were used to perform dosimetry calculations with the kidneys as source organs.
Results
The computational expense of the algorithm was sufficient for clinical daily routine, required minimum pre-processing and performed with acceptable accuracy a Dice coefficient of $$93\%$$
93
%
for liver segmentation and of $$94\%$$
94
%
for kidney segmentation, respectively. In addition, kidney self-absorbed doses calculated using automated segmentation differed by $$7\%$$
7
%
from dosimetry performed by two medical physicists in 8 patients.
Conclusion
The proposed approach may accelerate volumetric dosimetry of kidneys in molecular radiotherapy with 177Lu-labelled radiopharmaceuticals such as 177Lu-DOTATOC. However, even though a fully automated segmentation methodology based on CT images accelerates organ segmentation and performs with high accuracy, it does not remove the need for supervision and corrections by experts, mostly due to misalignments in the co-registration between SPECT and CT images.
Trial registration EudraCT, 2016-001897-13. Registered 26.04.2016, www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001897-13.
Funder
H2020 Marie Skłodowska-Curie Actions
Technische Universität Dresden
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging
Reference46 articles.
1. Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. OncoTargets Ther. 2017;10:551.
2. Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack H-J, Sabet A. Outcome of peptide receptor radionuclide therapy with 177 lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925–33.
3. Romer A, Seiler D, Marincek N, Brunner P, Koller M, Ng QK-T, Maecke H, Müller-Brand J, Rochlitz C, Briel M, et al. Somatostatin-based radiopeptide therapy with [177 lu-dota]-toc versus [90 y-dota]-toc in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(2):214–22.
4. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 psma radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60.
5. Bolch W, Bouchet L, Robertson J, Wessels B, Siegel J, Howell R, Erdi A, Aydogan B, Costes B, Watson E. The dosimetry of nonuniform activity distributions-radionuclide s values at the voxel level. mird pamphlet no. 17. J Nucl Med. 1999;40:11–36.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献